Loading...
Header Logo
Keywords
Last Name
Institution

FRANK V FOSSELLA

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Malek A, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich V, Viola G, Raad I. Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis. 2020 Jun 21. PMID: 32564081.
      View in: PubMed
    2. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 Sep; 15(9):1449-1459. PMID: 32389639.
      View in: PubMed
    3. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Jul 15; 26(14):3525-3536. PMID: 32193228.
      View in: PubMed
    4. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      View in: PubMed
    5. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547. PMID: 31386610.
      View in: PubMed
    6. Hui D, Kilgore K, Park M, Liu D, Kim YJ, Park JC, Fossella F, Bruera E. Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists. Oncologist. 2018 10; 23(10):1230-1235. PMID: 29895629.
      View in: PubMed
    7. Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822. PMID: 29293386.
      View in: PubMed
    8. Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424. PMID: 29217088.
      View in: PubMed
    9. Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737. PMID: 29248169.
      View in: PubMed
    10. Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017 10; 112:90-95. PMID: 29191606.
      View in: PubMed
    11. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147.
      View in: PubMed
    12. Waxman ES, Fossella FV. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. J Adv Pract Oncol. 2016 Jul-Aug; 7(5):514-524. PMID: 29282427.
      View in: PubMed
    13. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1. PMID: 27330023.
      View in: PubMed
    14. Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016 06; 34(3):290-9. PMID: 26961907.
      View in: PubMed
    15. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015 Jul; 26(7):1440-6. PMID: 26041765.
      View in: PubMed
    16. Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. Am J Clin Oncol. 2014 Feb; 37(1):77-80. PMID: 23111360.
      View in: PubMed
    17. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906.
      View in: PubMed
    18. Milbury K, Badr H, Fossella F, Pisters KM, Carmack CL. Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer. Support Care Cancer. 2013 Sep; 21(9):2371-9. PMID: 23546537.
      View in: PubMed
    19. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013 Mar 13; 3(3). PMID: 23485717.
      View in: PubMed
    20. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      View in: PubMed
    21. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319.
      View in: PubMed
    22. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8. PMID: 21555682.
      View in: PubMed
    23. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7. PMID: 21489716.
      View in: PubMed
    24. Blumenschein GR, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98. PMID: 22820084.
      View in: PubMed
    25. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):64-70. PMID: 21119545.
      View in: PubMed
    26. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      View in: PubMed
    27. William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8. PMID: 20225327.
      View in: PubMed
    28. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727.
      View in: PubMed
    29. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10; 27(26):4274-80. PMID: 19652055.
      View in: PubMed
    30. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009 Mar; 14(3):253-63. PMID: 19221167.
      View in: PubMed
    31. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349. PMID: 19059972.
      View in: PubMed
    32. Carmack Taylor CL, Badr H, Lee JH, Fossella F, Pisters K, Gritz ER, Schover L. Lung cancer patients and their spouses: psychological and relationship functioning within 1 month of treatment initiation. Ann Behav Med. 2008 Oct; 36(2):129-40. PMID: 18797978.
      View in: PubMed
    33. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27. PMID: 18556142.
      View in: PubMed
    34. Kennedy MP, Jimenez CA, Chang J, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J. 2008 Apr; 31(4):902-3. PMID: 18378785.
      View in: PubMed
    35. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC. Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):294-314. PMID: 18377848.
      View in: PubMed
    36. de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):30-6. PMID: 18166838.
      View in: PubMed
    37. Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol. 2007 Oct; 2(10):939-46. PMID: 17909357.
      View in: PubMed
    38. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007 Jun 06; 99(11):847-57. PMID: 17551145.
      View in: PubMed
    39. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      View in: PubMed
    40. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60. PMID: 17322539.
      View in: PubMed
    41. Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol. 2007 Feb; 2(2):141-6. PMID: 17410030.
      View in: PubMed
    42. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5025-33. PMID: 17075122.
      View in: PubMed
    43. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):602-22. PMID: 16813728.
      View in: PubMed
    44. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer. 2006 Aug; 53(2):231-9. PMID: 16787687.
      View in: PubMed
    45. Montoya M, Fossella F, Palmer JL, Kaur G, Pace EA, Yadav R, Simmonds M, Gillis T, Bruera E. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med. 2006 Apr; 9(2):309-16. PMID: 16629561.
      View in: PubMed
    46. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      View in: PubMed
    47. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005 Dec 15; 104(12):2766-74. PMID: 16288485.
      View in: PubMed
    48. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56. PMID: 16258975.
      View in: PubMed
    49. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005 Dec 20; 23(36):9089-96. PMID: 16301597.
      View in: PubMed
    50. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9. PMID: 16028213.
      View in: PubMed
    51. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8. PMID: 15867233.
      View in: PubMed
    52. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8. PMID: 15837739.
      View in: PubMed
    53. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8. PMID: 16015542.
      View in: PubMed
    54. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005 Apr; 6(4):229-39. PMID: 15811618.
      View in: PubMed
    55. Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):54-62. PMID: 15339061.
      View in: PubMed
    56. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14. PMID: 15184994.
      View in: PubMed
    57. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun; 44(3):369-79. PMID: 15140551.
      View in: PubMed
    58. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97. PMID: 15117980.
      View in: PubMed
    59. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76. PMID: 15131032.
      View in: PubMed
    60. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77. PMID: 15050312.
      View in: PubMed
    61. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004 Apr; 44(1):99-110. PMID: 15013588.
      View in: PubMed
    62. Fossella FV. Pemetrexed for treatment of advanced non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):100-5. PMID: 14981587.
      View in: PubMed
    63. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11. PMID: 14981588.
      View in: PubMed
    64. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12. PMID: 14697440.
      View in: PubMed
    65. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15; 21(16):3016-24. PMID: 12837811.
      View in: PubMed
    66. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      View in: PubMed
    67. Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J, Fossella F, Allen P, Cox JD, Komaki R. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):616-25. PMID: 12788166.
      View in: PubMed
    68. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21. PMID: 12886869.
      View in: PubMed
    69. Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91. PMID: 12796372.
      View in: PubMed
    70. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101. PMID: 12538456.
      View in: PubMed
    71. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003 Jan; 39(1):55-61. PMID: 12499095.
      View in: PubMed
    72. Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer. 2002 Dec; 38 Suppl 4:5-12. PMID: 12480189.
      View in: PubMed
    73. Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer. 2002 Dec; 38 Suppl 4:43-9. PMID: 12480194.
      View in: PubMed
    74. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002 Nov 15; 20(22):4440-7. PMID: 12431966.
      View in: PubMed
    75. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      View in: PubMed
    76. Liao Z, Komaki R, Stevens C, Kelly J, Fossella F, Lee JS, Allen P, Cox JD. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):558-65. PMID: 12062597.
      View in: PubMed
    77. Fossella FV. Docetaxel for previously treated non-small-cell lung cancer. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):45-51. PMID: 12108897.
      View in: PubMed
    78. Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S23-8. PMID: 14720344.
      View in: PubMed
    79. Fossella FV, Gatzemeier U. Phase I trials of pemetrexed. Semin Oncol. 2002 Apr; 29(2 Suppl 5):8-16. PMID: 12023787.
      View in: PubMed
    80. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9. PMID: 11917284.
      View in: PubMed
    81. Komaki R, Chasen MH, Travis WD, Putnam JB, Fossella FV, Byhardt RW, Ro JY. Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. Radiographics. 2001 Nov-Dec; 21(6):1573-96. PMID: 11706227.
      View in: PubMed
    82. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer. 2001 Aug; 3(1):27-32. PMID: 14656386.
      View in: PubMed
    83. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol. 2001 Jun; 12(6):739-44. PMID: 11484947.
      View in: PubMed
    84. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001 Feb; 28(1 Suppl 2):4-9. PMID: 11284623.
      View in: PubMed
    85. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials. Semin Oncol. 2001 Feb; 28 Suppl 2:4-9. PMID: 28140080.
      View in: PubMed
    86. Perez-Cardona JH, Ordonez NG, Fossella FV. Lymph node micrometastases in non small-cell lung cancer: clinical applications. Clin Lung Cancer. 2000 Nov; 2(2):116-20. PMID: 14731321.
      View in: PubMed
    87. Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, Fossella FV, Chasen M, Delclos ME, Cox JD. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2000 Sep 01; 48(2):347-54. PMID: 10974447.
      View in: PubMed
    88. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000 Aug; 18(3):243-5. PMID: 10958592.
      View in: PubMed
    89. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun; 18(12):2354-62. PMID: 10856094.
      View in: PubMed
    90. Liu NS, Spitz MR, Kemp BL, Cooksley C, Fossella FV, Lee JS, Hong WK, Khuri FR. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. Cancer. 2000 Apr 15; 88(8):1837-41. PMID: 10760760.
      View in: PubMed
    91. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22. PMID: 10653876.
      View in: PubMed
    92. Fossella FV. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep. 2000 Jan; 2(1):96-101. PMID: 11122830.
      View in: PubMed
    93. Fossella F, Rigas JR, Belani CP. New options in the treatment of non-small cell lung cancer. Anticancer Drugs. 1999 Nov; 10 Suppl 1:S25-8. PMID: 10630365.
      View in: PubMed
    94. Fossella FV. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol. 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PMID: 10585004.
      View in: PubMed
    95. Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug; 17(8):2309-15. PMID: 10561292.
      View in: PubMed
    96. Fossella FV, Rigas J. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Semin Oncol. 1999 Jun; 26(3 Suppl 11):9-12. PMID: 10458204.
      View in: PubMed
    97. Fossella FV. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 11):4-8. PMID: 10458203.
      View in: PubMed
    98. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71. PMID: 10328106.
      View in: PubMed
    99. Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):479-86. PMID: 9806504.
      View in: PubMed
    100. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998 Jul; 21(1):1-6. PMID: 9792048.
      View in: PubMed
    101. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol. 1998 Jun; 25(3 Suppl 8):33-7. PMID: 9704675.
      View in: PubMed
    102. Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res. 1998 Apr; 18(4):241-5. PMID: 9568726.
      View in: PubMed
    103. Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer. 1998 Jan 15; 82(2):301-8. PMID: 9445186.
      View in: PubMed
    104. Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6. PMID: 9457817.
      View in: PubMed
    105. Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs. 1998-1999; 16(3):237-43. PMID: 10360603.
      View in: PubMed
    106. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan; 16(1):187-96. PMID: 9440742.
      View in: PubMed
    107. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs. 1998; 16(1):81-5. PMID: 9740548.
      View in: PubMed
    108. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4):455-62. PMID: 9280225.
      View in: PubMed
    109. Lee JS, Pisters KM, Komaki R, Glisson BS, Khuri FR, Schea R, Fossella FV. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-52-S12-55. PMID: 9331122.
      View in: PubMed
    110. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):149-55. PMID: 9212017.
      View in: PubMed
    111. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997 Jan; 15(1):310-6. PMID: 8996158.
      View in: PubMed
    112. Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):179-94. PMID: 8953602.
      View in: PubMed
    113. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 Oct; 14(10):2785-90. PMID: 8874340.
      View in: PubMed
    114. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol. 1996 Apr; 14(4):1055-64. PMID: 8648357.
      View in: PubMed
    115. Fossella FV, Rivera E, Roth JA. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol. 1996 Mar; 8(2):106-11. PMID: 8727302.
      View in: PubMed
    116. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13. PMID: 8636764.
      View in: PubMed
    117. Huber MH, Lee JS, Newman RA, Fossella FV, Wester M, Hong WK, Lippman SM. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol. 1996 Jan; 7(1):59-63. PMID: 9081393.
      View in: PubMed
    118. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer. 1995 Dec 01; 76(11):2230-6. PMID: 8635025.
      View in: PubMed
    119. Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol. 1995 Jun; 13(6):1501-8. PMID: 7751898.
      View in: PubMed
    120. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 4):22-9. PMID: 7740327.
      View in: PubMed
    121. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar; 13(3):645-51. PMID: 7884425.
      View in: PubMed
    122. Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ, et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):807-11. PMID: 7860392.
      View in: PubMed
    123. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12(6):1238-44. PMID: 7911160.
      View in: PubMed
    124. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 04; 86(9):673-80. PMID: 8158698.
      View in: PubMed
    125. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994 Jan; 35(1):63-9. PMID: 7505819.
      View in: PubMed
    126. Goeckeler WF, Stoneburner LK, Kasi LP, Fossella FV, Price DR, Fordyce WA. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol. 1993 Jul; 20(5):657-61. PMID: 8358352.
      View in: PubMed
    127. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 03; 85(5):384-8. PMID: 8094466.
      View in: PubMed
    128. Munshi NC, Seitz DE, Fossella F, Lippman SM, Einhorn LH. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest New Drugs. 1993 Feb; 11(1):87-90. PMID: 8394298.
      View in: PubMed
    129. Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, Young JA, Readling J, Bowers B, Hong WK. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs. 1992 Nov; 10(4):331-5. PMID: 1336771.
      View in: PubMed
    130. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Jul 01; 84(13):1039-40. PMID: 1318977.
      View in: PubMed
    131. Shin DM, Dhingra HM, Lee JS, Fossella FV, Murphy WK, Hong WK. Phase II study of combination therapy with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small-cell lung cancer. Am J Clin Oncol. 1992 Jun; 15(3):194-9. PMID: 1317094.
      View in: PubMed
    132. Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small-cell lung cancer. Compr Ther. 1992 Mar; 18(3):27-30. PMID: 1315236.
      View in: PubMed
    133. Fossella FV, Lippman SM, Seitz DE, Alberts DS, Taylor CW, Wiltshaw E, Hardy J, O'Brien M, Haynes TR, Wolen RL. Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: report of three cases. Invest New Drugs. 1991 Nov; 9(4):357-9. PMID: 1804813.
      View in: PubMed
    134. Fossella FV, Winn RJ, Holoye PY, Raber MN, Holden L, Belt R, Allen H, Hallinan B, Harper K. Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs. 1991 Nov; 9(4):375-6. PMID: 1666631.
      View in: PubMed
    135. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer. 1991 Sep 01; 68(5):959-64. PMID: 1655220.
      View in: PubMed
    136. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5. PMID: 1846848.
      View in: PubMed
    137. Tuma SN, Orson F, Fossella FV, Waidhofer W. Seizures and dermatitis after exposure to caprolactam. Arch Intern Med. 1981 Oct; 141(11):1544-5. PMID: 7283571.
      View in: PubMed
    138. Small cell lung cancer. 63-75.
    139. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Investigational New Drugs. 1-10.
    140. Dexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.
    141. Single-agent docetaxel in patients with refractory non-small-cell lung cancer. Oncology. 11:11-15.
    142. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer. Seminars in Oncology. 24.
    143. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    144. Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma. 283-314.
    FOSSELLA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description